VIRILON Drug Patent Profile
Which patents cover Virilon, and when can generic versions of Virilon launch?
Virilon is a drug marketed by Chartwell and is included in one NDA.
The generic ingredient in VIRILON is methyltestosterone. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the methyltestosterone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Virilon
A generic version of VIRILON was approved as methyltestosterone by IMPAX LABS on December 31st, 1969.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VIRILON?
- What are the global sales for VIRILON?
- What is Average Wholesale Price for VIRILON?
Summary for VIRILON
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 49 |
| Clinical Trials: | 2 |
| Patent Applications: | 4,215 |
| DailyMed Link: | VIRILON at DailyMed |
Recent Clinical Trials for VIRILON
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Washington | Phase 2 |
| National Cancer Institute (NCI) | Phase 2 |
| Emory University | Phase 1 |
US Patents and Regulatory Information for VIRILON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chartwell | VIRILON | methyltestosterone | CAPSULE;ORAL | 087750-001 | Nov 24, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
